Cynthia Brinson, MD

Medical Director
Central Texas Clinical Research

Disclosure: Gilead (Individual(s) Involved: Self): Advisor or Review Panel member, Speakers' bureau; ViiV Healthcare (Individual(s) Involved: Self): Advisor or Review Panel member, Speakers' bureau

Presentation(s):

• 116 - Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

  Oral Abstract